Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.36 USD | +5.93% | +5.37% | -19.58% |
02:56pm | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.58% | 2.22B | |
+25.04% | 46.71B | |
+48.83% | 41.8B | |
-1.11% | 41.52B | |
-3.42% | 29.55B | |
+10.63% | 25.78B | |
-20.94% | 19.26B | |
+1.66% | 12.14B | |
-3.59% | 12.08B | |
+27.26% | 11.98B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating